Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

By Li Yuqin  

Wiener klinische Wochenschrift, Vol. 122, Iss. 13-14, 2010-07 ,pp. : 413-422

Springer Publishing Company

Access to resources Recommend Favorite

Rabeprazole‐based therapy in Helicobacter pylori eradication

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 16, Iss. s1, 2002-03 ,pp. : 31-33

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐day triple therapy versus sequential therapy versus concomitant therapy as first‐line treatment for Helicobacter pylori infection

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1134-1139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 581-589

John Wiley & Sons Inc

Access to resources Recommend Favorite

Helicobacter pylori treatment in children: Defining a dose for rabeprazole as a part of a triple therapy regimen

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 5, 2015-05 ,pp. : 592-600

John Wiley & Sons Inc

Access to resources Recommend Favorite